Theoretical stack · Longevity & Mitochondrial Health

NAD+ Precursor + Epitalon

Cellular metabolism + telomere axis

Emerging · By Editorial Team at ModernPeptideScience · Last reviewed: May 2026

Theoretical educational discussion

This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.

Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.

At a glance

Two of the most-discussed longevity interventions paired across substantially different aging-biology axes. NAD+ precursors (NR or NMN) target the sirtuin / metabolic / mitochondrial axis; Epitalon targets the telomere / pineal / circadian axis from the Khavinson tradition. Mechanistically orthogonal, anecdotally popular, controlled-evidence-thin for the combination.

Compounds in the stack

Each compound's role in the combination, with link to its full peptide page for the underlying research.

5-Amino-1MQ

NAD+-pathway proxy on the peptide side — NNMT inhibitor that preserves the cellular NAD+ pool by reducing nicotinamide methylation and disposal. Stands in here for the broader NAD+-precursor approach (NR, NMN, niacin) most users actually take orally.

Preclinical · Investigational

Epitalon

Khavinson-tradition synthetic tetrapeptide (Ala-Glu-Asp-Gly) reported to influence telomerase activity, pineal function, and circadian regulation. Multi-decade originating-group data; limited Western replication.

Investigational · Khavinson framework

Mechanistic rationale

The pairing rests on a deliberately orthogonal-mechanism framing: address two substantially different aging-biology axes rather than stacking compounds with overlapping effects.

The NAD+ axis — sirtuin-dependent metabolic and mitochondrial regulation, DNA repair via PARP biology, immune-cell NAD+ consumption via CD38. NAD+ levels measurably decline with age in many tissues, and the supplement layer (NR, NMN, niacin) raises blood NAD+ reliably. 5-Amino-1MQ approaches the same axis from a different angle by inhibiting NNMT, the enzyme that disposes of nicotinamide and depletes the methyl-donor pool that NAD+ biosynthesis depends on.
The telomere / pineal axis — replicative aging at the cellular level, telomerase activity (the enzyme that maintains telomere length), and the pineal/circadian regulatory output that Khavinson framework research emphasizes. Epitalon is the most-cited member of the Khavinson short-peptide system with the longest research record in this tradition.

The combination logic is that these two systems address different drivers of cellular aging, and that targeting both simultaneously might do more than targeting either alone. Neither system claims the other's biology — they're conceptually complementary rather than redundant.

A caveat on what "NAD+" actually means in practice for this stack. Most users approaching this combination are taking an oral NAD+ precursor (NR or NMN are most common; nicotinamide and niacin are cheaper alternatives) rather than the peptide compound listed here. 5-Amino-1MQ is the closest peptide-page proxy on this site for the broader NAD+/NNMT/methyl-pool pathway. The NAD+ forms guide walks through the practical differences between NR, NMN, IV NAD+, and the various oral options for users implementing this pathway directly.

Human and emerging evidence

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

Human research

NAD+ precursors (NR and NMN) — multiple Phase 1/2 human trials demonstrate that NR and NMN reliably raise blood NAD+ levels at typical doses (250-1000 mg/day). Functional signals are modest and mixed across endpoints (muscle insulin sensitivity, aerobic capacity, blood pressure, sleep). No trial has tested aging endpoints over a meaningful timeframe.
5-Amino-1MQ specifically — preclinical only as of 2026. No human efficacy trials. The NNMT-inhibition rationale is supported by mouse models showing metabolic improvements.
Epitalon — Russian-language clinical studies including multi-year mortality follow-up from the Khavinson group, reporting reduced all-cause mortality compared to non-treated reference groups. Not independently replicated at the level required by Western evidence standards. Cell-culture and animal-model work supports the telomerase-activation claim within the originating-lineage publications.
The combination — no human evidence whatsoever. The pairing is built on individual-compound rationales rather than combination-specific research.

Reported user experiences

The reports below are aggregated from research forums, podcasts, and user-community discussions. They are useful as hypothesis-generating signals but are not controlled clinical data — selection bias, placebo response, and underreporting of adverse effects all apply.

The longevity-peptide and biohacker communities have substantial discussion of pairing NAD+ precursors with Khavinson peptides like Epitalon. Reports are characteristically subjective and short-term:

Improved sleep architecture (frequently attributed to Epitalon specifically; some users report melatonin-rhythm-related changes).
Subjective energy and recovery improvements (often attributed to the NAD+ side).
Skin and physical-resilience changes over months of cyclic use.
Cognitive and mood-related effects, particularly during Epitalon courses.

These reports are useful as hypothesis-generating signals but are not controlled data — they're subject to placebo response, selection effects (people who feel benefit talk about it more), and the natural variability of subjective endpoints over weeks to months. The combination has not been studied with controlled designs that would resolve which effects are real, which are individual-compound effects, and which are due to the pairing.

Potential benefits and risks

Potential benefits

Two mechanistically orthogonal axes — minimal overlap, conceptually complementary
Each component has individually credible mechanistic biology
Oral NAD+ precursors (NR / NMN / niacin) are accessible at moderate cost
Both interventions are generally well-tolerated short-term in user reports
Pairs well with the broader lifestyle-foundation approach to healthspan

Potential risks

No combination-specific human evidence — the pairing rationale is mechanistic inference
Epitalon's positive evidence comes overwhelmingly from one Russian research lineage
5-Amino-1MQ is preclinical only; oral NAD+ precursors have human safety data but no demonstrated longevity outcomes
Long-term safety of either intervention over decades is uncharacterized
Source-quality and identity concerns for both Epitalon (grey-market peptide) and some NAD+ products (regulatory and quality variability)
Cost can compound substantially — IV NAD+ specifically runs $300-1500/session, often used in series
Anecdotal reports may overestimate effect sizes due to placebo, selection bias, and short observation windows

Open questions

Does combining NAD+ precursor supplementation with Epitalon produce additive or synergistic effects on any measurable endpoint?
Are the subjective effects reported by users attributable to the combination or to either component individually?
Does either component, alone or combined, extend healthspan or affect age-related disease incidence in controlled human studies?
What is the optimal NAD+ form to pair with Epitalon — does it matter whether you use NR, NMN, niacin, or IV?
Are there theoretical interactions (positive or negative) between sirtuin pathway activation and Khavinson-tradition cellular signaling?

The takeaway

This pairing is one of the more thoughtful combinations in the longevity-peptide space because the two components target genuinely different biological axes — there's a coherent argument for why combining them might do more than either alone. The combination is also one of the least-validated by controlled human evidence: no trial has tested the pairing, and both components individually have substantially more biomarker evidence than outcome evidence.

For readers drawn to the longevity space and intending to implement this approach, the practical framing matters. The NAD+ side is most accessibly approached through oral NR or NMN — the NAD+ forms guide walks through how the different forms compare on evidence and cost. The Epitalon side is approached through the grey-market peptide market with the source-quality considerations that go with it. Both layers should sit on top of the well-supported lifestyle foundations of healthspan (sleep, exercise, nutrition, cardiometabolic risk-factor management), not as substitutes for them.

The honest read: this is an interesting bet on an under-studied combination. It's not evidence-based longevity medicine, and anyone framing it that way is overstating what the data shows.

References

Rajman L, et al. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. https://pubmed.ncbi.nlm.nih.gov/29514064/
Khavinson VK, et al. Peptide regulation of aging: 35-year research experience. Bull Exp Biol Med. 2014;156(6):824-8. https://pubmed.ncbi.nlm.nih.gov/24824962/
Anisimov VN, et al. Effect of Epitalon on biomarkers of aging. Exp Gerontol. 2003;38(4):449-461. https://pubmed.ncbi.nlm.nih.gov/12670631/
Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. https://pubmed.ncbi.nlm.nih.gov/29599478/
Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. https://pubmed.ncbi.nlm.nih.gov/24786309/